At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reproductive Hormonal Alterations in Obesity, AIMS #1 & #2
In Brief
A clinical study evaluating Cetrorelix, Gonadorelin-GnRH, and 2 other interventions for Obesity. Completed, enrolled 62 participants across 1 site.
Detailed Summary
The purpose of this study is to determine why obese women have lower hormone levels and less fertility than women of normal body weight. The proposal will examine the reproductive system at the level of the brain and the ovary to define the changes that happen leading to lowered hormone production. Women will be studied throughout a menstrual cycle and given medications that will test how well their pituitary gland can make hormones that stimulate the ovary (luteinizing hormone (LH) and follicle stimulating hormone (FSH)). They will also be given a medication to abolish estrogen production in the body and their response to this medication will be assessed. Finally, the ovary's ability to produce progesterone after ovulation will be examined. --Hypotheses: 1. Obese women have reduced pituitary sensitivity to exogenous gonadotropin-releasing hormone (GnRH), but normal clearance of exogenous LH. (comparative study of obese compared to normal weight women) 2. Obese women have abnormally increased sensitivity to estradiol negative feedback which will be reversed by an aromatase inhibitor. (comparative study of obese compared to normal weight women)
Study Details
Timeline
Interventions
Abolishes pituitary sensitivity to GnRH.
GnRH is used to stimulate the pituitary gland to produce LH and FSH.
Used to stimulate ovarian function in women.
An aromatase inhibitor.